Statistics

Total Visits

Views
Apremilast, an oral phosphodiesterase 4 inhibitor, is associated with long-term (52-week) improvement in measures of disease activity in patients with psoriatic arthritis: Results from 3 phase 3, randomized, controlled trials161

Select a period of time:

Number of views in the range

Views
Apremilast, an oral phosphodiesterase 4 inhibitor, is associated with long-term (52-week) improvement in measures of disease activity in patients with psoriatic arthritis: Results from 3 phase 3, randomized, controlled trials66

Views

Views
November 20255
December 20254
January 202617
February 20261
March 202622
April 20266
May 202611
Download CSV file
 untranslated
 untranslated

Top country views

Views
United States30
United Kingdom5
Mauritius3
Canada3
Argentina2
Australia2
Brazil2
Congo2
China2
Ecuador2
 

Top cities views

Views
San Jose9
Chelmsford4
Ashburn4
Guayaquil2
Istanbul2
Los Angeles2
Barquisimeto2
Al Ma`adi1
Amsterdam1
Basildon1